Targeted drug combination shows unprecedented activity in some highly aggressive brain tumors
A combination of two targeted cancer drugs showed unprecedented, "clinically meaningful" activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by ...